G1 Therapeutics (GTHX) Scheduled to Post Quarterly Earnings on Wednesday

G1 Therapeutics (NASDAQ:GTHXGet Rating) is set to issue its quarterly earnings data before the market opens on Wednesday, May 4th. Analysts expect the company to announce earnings of ($0.98) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

G1 Therapeutics (NASDAQ:GTHXGet Rating) last issued its quarterly earnings data on Wednesday, February 23rd. The company reported ($0.94) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.03) by $0.09. The business had revenue of $5.80 million for the quarter, compared to the consensus estimate of $5.45 million. G1 Therapeutics had a negative net margin of 471.32% and a negative return on equity of 76.03%. During the same period in the previous year, the firm earned ($0.67) EPS. On average, analysts expect G1 Therapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Shares of G1 Therapeutics stock opened at $5.93 on Wednesday. The company has a current ratio of 8.82, a quick ratio of 8.69 and a debt-to-equity ratio of 0.52. The company’s fifty day simple moving average is $8.46 and its two-hundred day simple moving average is $10.57. The company has a market cap of $253.25 million, a P/E ratio of -1.68 and a beta of 1.93. G1 Therapeutics has a 12-month low of $5.91 and a 12-month high of $24.12.

A number of brokerages have issued reports on GTHX. Zacks Investment Research downgraded shares of G1 Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday. Needham & Company LLC restated a “buy” rating and set a $44.00 target price on shares of G1 Therapeutics in a report on Thursday, April 14th. Two analysts have rated the stock with a sell rating and five have assigned a buy rating to the company. According to MarketBeat.com, G1 Therapeutics has a consensus rating of “Hold” and an average price target of $37.00.

Institutional investors have recently made changes to their positions in the stock. Royal Bank of Canada boosted its stake in G1 Therapeutics by 69.0% in the 3rd quarter. Royal Bank of Canada now owns 5,254 shares of the company’s stock worth $71,000 after purchasing an additional 2,145 shares in the last quarter. BNP Paribas Arbitrage SA lifted its stake in G1 Therapeutics by 479.1% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 7,772 shares of the company’s stock valued at $104,000 after acquiring an additional 6,430 shares during the period. Guggenheim Capital LLC bought a new position in G1 Therapeutics during the 4th quarter valued at about $106,000. Squarepoint Ops LLC bought a new position in G1 Therapeutics during the 4th quarter valued at about $152,000. Finally, MetLife Investment Management LLC lifted its stake in G1 Therapeutics by 50.5% during the 4th quarter. MetLife Investment Management LLC now owns 14,959 shares of the company’s stock valued at $153,000 after acquiring an additional 5,019 shares during the period. Institutional investors own 63.73% of the company’s stock.

G1 Therapeutics Company Profile (Get Rating)

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.

Further Reading

Earnings History for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.